NCT06205277Completed
Predictors of Residual Tumor at Second Transurethral Resection for pT1 Non-muscle Invasive Bladder Cancer
Source: ClinicalTrials.gov · Last updated 12 Jan 2024
Brief summary (registry, in English)
The START study is a multicentre retrospective project. The aim is to identify clinico-pathological predictors of residual tumor at time of second transurethral resection of bladder tumor (re-TURBt) and to identify well-selected candidates for a risk-adapted strategy in which this procedure could be safely spared.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 1300 (actual)
- First submitted
- 3 Jan 2024
- Start date
- 1 Jan 2022
- Primary completion date
- 31 Dec 2023
- Lead sponsor
- University of Trieste
- Diseases
- Bladder cancer
- NCT number
- NCT06205277
What you commit to
- Study type: Observational
- Participants enrolled: 1300
- From 1 Jan 2022 to the primary completion date, 31 Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- patients with incomplete resection at time of first TURBt according to surgeon: macroscopic evidence of residual tumor, too long resection requiring a second-look will be excluded from the current study;
Other
- patients with clinical non-localized BCa (cN+, cM+);
- patients with incomplete clinical or demographic or pathological data;
- patients who were unable to provide written informed consent;
- patients who underwent urgency or emergency procedures in life-threating scenario
Who the study is looking for
- patients undergoing second TURBt (re-TURBt) for pT1LG/HG NMIBC after a macroscopically completed first TURBt (in patients with multiple lesions only the index lesion pT1 conditioning the indication of re-TURBt will be considered). Therefore, presence of residual tumor or not at time of re-TURBt will be assessed at site of previous pT1.
- patients able to provide written informed consent;
- clinical-localized non-metastatic disease (cN0, cM0).
Age in the registry: 18 years to - · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Trieste - Azienda Ospedaliera Universitaria Giuliano Isontina Coordinator of this site? Confirm its status | Trieste | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.